Cancer Stem Cell News Volume 9.11 | Mar 25 2020

TOP STORY

DAXX Inhibits Cancer Stemness and Epithelial-Mesenchymal Transition in Gastric Cancer

Scientists investigated the molecular mechanisms by which DAXX downregulation promoted cancer growth using both in vitro and in vivo models. [Br J Cancer] Abstract

(Ranked by impact factor of the journal)

Targeting Prostate Cancer Stem-Like Cells by an Immunotherapeutic Platform Based on Immunogenic Peptide-Sensitized Dendritic Cells-Cytokine-Induced Killer Cells

The in vitro cytotoxic activity of dendritic cell-activated cytokine-induced killer cell cells against prostate cancer stem-like cells was determined by CCK8 and TUNEL assays. [Stem Cell Res Ther] Full Article

Membrane Metalloendopeptidase Suppresses Prostate Carcinogenesis by Attenuating Effects of Gastrin-Releasing Peptide on Stem/Progenitor Cells

Scientists report that membrane metalloendopeptidase cooperated with PTEN in suppression of carcinogenesis by controlling activities of prostate stem/progenitor cells. [Oncogenesis] Full Article

The LSD1 Inhibitor Iadademstat (ORY-1001) Targets SOX2-Driven Breast Cancer Stem Cells: A Potential Epigenetic Therapy in Luminal-B and HER2-Positive Breast Cancer Subtypes

Iadademstat blocked CSC-driven mammosphere formation in breast cancer cell lines that were dependent on SOX2 expression to maintain their CSC phenotype. [Aging (Albany NY)] Full Article

CD44⁺CD24^-/low Sphere-Forming Cells of EBV-Associated Gastric Carcinomas Show Immunosuppressive Effects and Induce Tregs Partially through Production of PGE2

Investigators isolated CSC-like sphere-forming cells from EBV-associated gastric carcinoma cell line using the cancer sphere method. They validated their CSC-associated properties in the expression of the epithelial-mesenchymal transition-related genes. [Exp Cell Res] Abstract

Murine Hepatoblast-Derived Liver Tumors Resembling Human Combined Hepatocellular-Cholangiocarcinoma with Stem Cell Features

Investigators confirmed that p53^-/- murine hepatoblasts acted as tumor-initiating cells that generated combined hepatocellular-cholangiocarcinoma both in situ and within metastases. [Cell Biosci] Full Article

A New Tyrosine Kinase Inhibitor K905-0266 Inhibits Proliferation and Sphere Formation of Glioblastoma Cancer Cells

Researchers assessed whether inhibition of glioblastoma (GBM) and GBM-derived CSCs by a new tyrosine kinase inhibitor (TKI), K905-0266, was possible. They generated GBM cells expressing luciferase and characterized the inhibitory effects of the TKI with bioluminescent imaging and western blot. [J Drug Target] Abstract

Poziotinib Suppresses Ovarian Cancer Stem Cell Growth via Inhibition of HER4-Mediated STAT5 Pathway

Poziotinib, a pan-human epidermal growth factor receptor inhibitor, decreased sphere formation, viability, and proliferation, and induced G1 cell cycle arrest and apoptosis in ovarian CSCs. [Biochem Biophys Res Commun] Abstract

DDIT3 Modulates Cancer Stemness in Gastric Cancer by Directly Regulating CEBPβ

Researchers showed that DNA damage-inducible transcript 3 (DDIT3) expression was increased in gastric cancer (GC) tissues. qRT-PCR confirmed that DDIT3 was significantly increased in GC tissues and cancer cell lines compared with healthy tissues and normal cell lines, individually. [J Pharm Pharmacol] Abstract

Basal-Type Breast Cancer Stem Cells Over-Express Chromosomal Passenger Complex Proteins

The authors found that CSCs presented marked differences from the non-CSCs, including enrichment in transduction cascades related to stemness, cellular growth, proliferation and apoptosis. [Cells] Full Article

Subscribe to one of our other 19 science newsletters such as Neural Cell News & Hematopoiesis News.

Ovarian Cancer Stem Cells: Ready for Prime Time?

The authors review all the relevant literature that addresses the oncogenetic potential of stem cells in epithelial ovarian cancer, their mechanisms, and the associated therapeutic targets. [Arch Gynecol Obstet] Abstract

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

Genentech Announces Venclexta Combination Improved Overall Survival in People with Previously Untreated Acute Myeloid Leukemia

Genentech, Inc. announced that the Phase III VIALE-A study met its dual primary endpoints of overall survival and composite complete remission rate. Venclexta^® in combination with azacitidine, a hypomethylating agent, showed a statistically significant improvement in overall survival in people with previously untreated acute myeloid leukemia who were ineligible for intensive induction chemotherapy, compared to azacitidine alone. [Genentech, Inc.] Press Release

Roche Announces Venclexta/Venclyxto Combination Improved Overall Survival in People with Previously Untreated Acute Myeloid Leukemia

Roche announced that the Phase III VIALE-A study met its dual primary endpoints of overall survival and composite complete remission rate. Venclexta®/Venclyxto^® in combination with azacitidine, a hypomethylating agent, showed a statistically significant improvement in overall survival in people with previously untreated acute myeloid leukemia who were ineligible for intensive induction chemotherapy, compared to azacitidine alone. [F. Hoffmann-La Roche Ltd] Press Release

Researchers Are Tracking Another Epidemic, Too-of Misinformation

When five researchers at the University of Washington, Seattle, launched the new Center for an Informed Public back in December 2019, they had no idea what was coming. The center aims to study how misinformation propagates and use the findings to “promote an informed society, and strengthen democratic discourse.” Now, just a few months later, the coronavirus pandemic is generating a tidal wave of information-some of it accurate, some not so much-that has saturated social and traditional media. [ScienceInsider] Editorial

After Conference Cancellations, Some Scientists Find a Way

As scores of academic meetings get upended due to COVID-19, researchers are turning to virtual replacements. [The Scientist] Editorial

In light of COVID-19, many conferences are being cancelled or postponed. As such:

We are suspending new event postings in our newsletters and on Twitter.
We will strive to keep our current event listings updated with event status.
We encourage you to visit event sites directly for updates.

Visit our events page to see a complete list of events in the community.

NEW Associate Professor – Regenerative Medicine (Guangzhou Regenerative Medicine and Health Guangdong Laboratory)

Postdoctoral Position – Glioma Epigenomic Research (NIH National Cancer Institute)

Postdoctoral Fellow – RAS Proteins and Cancer Cell Stemness (University of Luxembourg)

Postdoctoral Position – Leukemia and Cancer Stemness (Moores Cancer Center, UC San Diego)

Research Fellow – Leukemia Stem Cell Research (Dana Farber Cancer Institute)

Postdoctoral Fellow – Breast Cancer Stem Cells (Albert Einstein College of Medicine)

Research Fellow – Leukemia Stem Cell Biology (University College London)

Postdoctoral Scientist – Stem Cell Biology in Leukemia (University of Manchester)

Postdoctoral Fellow Position – RAS Cancer Cell Biology (University of Luxembourg)

Postdoctoral Researcher – Cancer Cell Invasiveness and Cancer Stem Cells (Cancer Research Center of Lyon)

Postdoctoral Associate – Glioma Stem Cell Biology (Cornell University)

Postdoctoral Research Fellowship – Cancer Biology and Stem Cell Biology (UT Southwestern Medical Center)

Postdoctoral Fellow – Translational Brain Tumor Research (Northwestern University)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.